ONC Valuation

BeOne Medicines AG

Add to Watchlist

Advanced Chart

319.970

-12.39(-3.728%)1D

ONC Relative Valuation

ONC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ONC is overvalued; if below, it's undervalued.

Historical Valuation

BeOne Medicines AG (ONC) is now in the Fair zone, suggesting that its current forward PE ratio of 91.75 is considered Fairly compared with the five-year average of 82.42. The fair price of BeOne Medicines AG (ONC) is between 23.80 to 497.36 according to relative valuation methord.

Relative Value

Fair Zone

23.80-497.36

Current Price：332.36

Fair

91.75

Trailing

Forward

47.30

EV/EBITDA

BeOne Medicines AG. (ONC) has a current EV/EBITDA of 47.30. The 5-year average EV/EBITDA is 19.86. The thresholds are as follows: Strongly Undervalued below -72.83, Undervalued between -72.83 and -26.48, Fairly Valued between 66.21 and -26.48, Overvalued between 66.21 and 112.55, and Strongly Overvalued above 112.55. The current Forward EV/EBITDA of 47.30 falls within the Historic Trend Line -Fairly Valued range.

80.42

EV/EBIT

BeOne Medicines AG. (ONC) has a current EV/EBIT of 80.42. The 5-year average EV/EBIT is 38.57. The thresholds are as follows: Strongly Undervalued below -92.53, Undervalued between -92.53 and -26.98, Fairly Valued between 104.12 and -26.98, Overvalued between 104.12 and 169.68, and Strongly Overvalued above 169.68. The current Forward EV/EBIT of 80.42 falls within the Historic Trend Line -Fairly Valued range.

332.36

BeOne Medicines AG. (ONC) has a current PS of 332.36. The 5-year average PS is 11.37. The thresholds are as follows: Strongly Undervalued below -67.45, Undervalued between -67.45 and -28.04, Fairly Valued between 50.78 and -28.04, Overvalued between 50.78 and 90.19, and Strongly Overvalued above 90.19. The current Forward PS of 332.36 falls within the Strongly Overvalued range.

26.94

P/OCF

BeOne Medicines AG. (ONC) has a current P/OCF of 26.94. The 5-year average P/OCF is 89.05. The thresholds are as follows: Strongly Undervalued below -198.88, Undervalued between -198.88 and -54.92, Fairly Valued between 233.02 and -54.92, Overvalued between 233.02 and 376.99, and Strongly Overvalued above 376.99. The current Forward P/OCF of 26.94 falls within the Historic Trend Line -Fairly Valued range.

60.18

P/FCF

BeOne Medicines AG. (ONC) has a current P/FCF of 60.18. The 5-year average P/FCF is 32.86. The thresholds are as follows: Strongly Undervalued below -268.13, Undervalued between -268.13 and -117.63, Fairly Valued between 183.36 and -117.63, Overvalued between 183.36 and 333.85, and Strongly Overvalued above 333.85. The current Forward P/FCF of 60.18 falls within the Historic Trend Line -Fairly Valued range.

BeOne Medicines AG (ONC) has a current Price-to-Book (P/B) ratio of 9.68. Compared to its 3-year average P/B ratio of 6.85 , the current P/B ratio is approximately 41.33% higher. Relative to its 5-year average P/B ratio of 6.85, the current P/B ratio is about 41.33% higher. BeOne Medicines AG (ONC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.58%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -1.58% , the current FCF yield is about -100.00% lower.

9.68

P/B

Median3y

6.85

Median5y

6.85

0.72

FCF Yield

Median3y

-1.58

Median5y

-1.58

Competitors Valuation Multiple

The average P/S ratio for ONC's competitors is 145.55, providing a benchmark for relative valuation. BeOne Medicines AG Corp (ONC) exhibits a P/S ratio of 332.36, which is 128.35% above the industry average. Given its robust revenue growth of 41.00%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ONC increased by 48.82% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.25 to -14.73.

The secondary factor is the Revenue Growth, contributed 41.00%to the performance.

Overall, the performance of ONC in the past 1 year is driven by P/E Change. Which is more unsustainable.

41.00%

1.00B → 1.41B

Revenue Growth

-172.94%

-12.12 → 8.84

Margin Expansion

180.76%

-5.25 → -14.73

P/E Change

48.82%